Syn­dax looks to re­bound from sting­ing late-stage fail­ure, un­cork­ing ear­ly da­ta for next can­cer drug up

A year ago, Syndax Pharmaceuticals suffered a major Phase III flop that forced it to forgo an FDA filing for its lead cancer drug and refocus on two earlier-stage programs. Now the biotech’s back with Phase I data on one of those candidates, and says it’s ready for a rebound — but investors aren’t fully convinced.